Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDPlus Therapeutics, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2025 | 2 | -$0.27 | -$0.23 | -$0.25 |
| Q2 2025 | 1 | -$0.13 | -$0.05 | -$0.09 |
| Q3 2025 | 2 | -$0.02 | -$0.02 | -$0.02 |
| Q4 2025 | 2 | -$0.05 | -$0.02 | -$0.03 |
| Q1 2026 | 2 | -$0.04 | -$0.03 | -$0.04 |
| Q2 2026 | 1 | -$0.08 | -$0.03 | -$0.05 |
| Q3 2026 | 1 | -$0.07 | -$0.03 | -$0.05 |
| Q4 2026 | 1 | -$0.07 | -$0.02 | -$0.04 |
| Q1 2027 | 1 | -$0.06 | -$0.02 | -$0.04 |
| Q2 2027 | 1 | -$0.05 | -$0.02 | -$0.03 |
| Q3 2027 | 1 | -$0.05 | -$0.02 | -$0.03 |
| Q4 2027 | 1 | -$0.05 | -$0.02 | -$0.03 |
| Q1 2028 | 1 | -$0.06 | -$0.02 | -$0.04 |
| Q2 2028 | 1 | -$0.05 | -$0.02 | -$0.03 |
| Q3 2028 | 1 | -$0.05 | -$0.02 | -$0.04 |
| Q4 2028 | 1 | -$0.04 | -$0.01 | -$0.03 |
Plus Therapeutics, Inc. Earnings Date And Information
Plus Therapeutics, Inc. last posted its earnings results on Thursday, October 30th, 2025. The company reported $-0.04 earnings per share for the quarter, missing analysts' consensus estimates of $-0.02 by $0.02. The company had revenue of 1.40 M for the quarter and had revenue of 5.82 M for the year. Plus Therapeutics, Inc. has generated $-2 earnings per share over the last year ($-2.34 diluted earnings per share) and currently has a price-to-earnings ratio of -3.29. Plus Therapeutics, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, November 13th, 2025 based on prior year's report dates.
Plus Therapeutics, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 10/30/2025 | Q3 2025 | -$0.02 | -$0.04 | -0.02 | $1.49 M | $1.40 M |
| 08/14/2025 | Q2 2025 | -$0.09 | $0.02 | 0.11 | $1.49 M | $1.39 M |
| 05/30/2025 | Q1 2025 | -$0.17 | -$1.19 | -1.02 | N/A | $1.06 M |
| 03/31/2025 | Q4 2024 | N/A | -$0.50 | N/A | N/A | $1.41 M |
| 11/14/2024 | Q3 2024 | -$0.46 | -$0.37 | 0.09 | $1.47 M | $1.46 M |
| 08/14/2024 | Q2 2024 | -$0.53 | -$0.45 | 0.08 | $1.70 M | $1.28 M |
| 05/15/2024 | Q1 2024 | -$1.09 | -$0.75 | 0.34 | N/A | $1.68 M |
| 03/05/2024 | Q4 2023 | -$0.78 | -$0.85 | -0.07 | N/A | $1.31 M |
| 10/31/2023 | Q3 2023 | -$0.58 | -$1.00 | -0.42 | $1.86 M | $1.24 M |
| 08/14/2023 | Q2 2023 | -$1.91 | -$0.59 | 1.32 | $1.05 M | $1.85 M |
| 04/20/2023 | Q1 2023 | -$2.10 | -$2.07 | 0.03 | $733.33 K | $506.00 K |
| 02/23/2023 | Q4 2022 | -$2.25 | -$2.56 | -0.31 | $1.48 M | $151.00 K |
| 10/20/2022 | Q3 2022 | -$3.15 | -$2.85 | 0.3 | $300.00 K | $73.00 K |
| 07/21/2022 | Q2 2022 | -$2.70 | -$3.56 | -0.86 | N/A | $0 |
| 04/21/2022 | Q1 2022 | -$2.55 | -$2.85 | -0.3 | N/A | $0 |
| 02/24/2022 | Q4 2021 | -$3.45 | -$4.05 | -0.6 | N/A | $0 |
| 10/21/2021 | Q3 2021 | -$3.15 | -$4.21 | -1.06 | N/A | $0 |
| 07/22/2021 | Q2 2021 | -$3.45 | -$3.72 | -0.27 | N/A | $0 |
| 07/06/2021 | Q1 2021 | N/A | -$4.93 | N/A | N/A | $0 |
| 02/22/2021 | Q4 2020 | -$4.95 | -$10.02 | -5.07 | N/A | $0 |
Explore Related Stocks for Market Trends
Explore our related stocks for the latest market trends and stock news to stay informed and make better decisions.
Plus Therapeutics, Inc. Earnings: FAQ's
Plus Therapeutics, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, November 13th, 2025 based offlast year's report dates.
The conference call for Plus Therapeutics, Inc.'s latest earnings report can be listened to online.
The conference call transcript for Plus Therapeutics, Inc.'s latest earnings report can be read online.
Plus Therapeutics, Inc. (:PSTV) has a recorded annual revenue of $5.82 M.
Plus Therapeutics, Inc. (:PSTV) has a recorded net income of $-12,978,000.Plus Therapeutics, Inc. has generated $-1.95 earnings per share over the last four quarters.
Plus Therapeutics, Inc. (:PSTV) has a price-to-earnings ratio of -3.29 and price/earnings-to-growth ratio is -0.2.